SNCA and Parkinson disease: Parkin gene therapy has been developed, using either AAV or lentiviral approaches, showing potential efficacy in the alpha-synuclein overexpression rat and macaque models of PD [92–94] and more recently in an MPTP mouse model of PD [95].